Xellia Pharmaceuticals Aps is a global leader in the development and manufacturing of specialty pharmaceuticals, particularly focusing on anti-infective treatments. Headquartered in Copenhagen, Denmark, the company specializes in complex injectable formulations and offers a range of products that address serious infections. Xellia is committed to advancing healthcare through innovative solutions and robust research in the fields of microbiology and pharmaceutical development, ensuring high-quality standards in its offerings.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

36 Patents

#12 in Copenhagen

#90 in Denmark

#18,730 in the World

Copenhagen, Denmark

Xellia Pharmaceuticals Aps

Forward Citations = 32

53 inventors:

Ivona Jasprica (8 out of 9 patents)

Sabina Keser (7 out of 8 patents)

Katarina Pindric (6 out of 6 patents)

4. Martin Mansson (5 out of 5 patents)

5. Torben Koch (5 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Xellia Pharmaceuticals Aps. Retrieved from https://idiyas.com/company/xellia-pharmaceuticals-aps

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

11 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

23 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]